Center experience: immunotherapy at the Royal Marsden
Novel therapies for the treatment of NSCLC: immunotherapy and targeted agents
Immunotherapy in second-line treatment of non-small cell lung cancer
ASCO 2018 bladder and kidney cancer highlights
Combining TKIs with checkpoint inhibitors for prostate cancer – is this the way forward?